BACKGROUND: Previous studies showed the prognostic and predictive impact of human epidermal growth factor receptor 2 (HER-2) gene alterations analyzed separately and jointly with topoisomerase II α (TOP2A) gene alterations; however, the role of TOP2A gene abnormalities alone has not been thoroughly investigated. Additionally, TOP2A aberrations were typically studied in HER-2-positive (HER-2(+)) tumors because these genes are frequently coamplified. Therefore, the knowledge concerning the impact of TOP2A abnormalities in HER-2-negative (HER-2(-)) patients is scarce. This study aimed to investigate the clinical significance of TOP2A anomalies in breast cancer patients with HER-2(-) and HER-2(+) tumors. MATERIALS AND METHODS: Snap-frozen tumor samples from 322 consecutive stage I-III breast cancer patients were analyzed for TOP2A gene dosage using quantitative real-time PCR (qPCR). RESULTS: A high TOP2A gene dosage was found in 94 tumors (29%)-32% and 27% of HER-2(+) and HER-2(-) tumors, respectively. The mean TOP2A gene dosages in the HER-2(+) and HER-2(-) groups were 1.49 ± 1.03 and 1.09 ± 0.35, respectively. High TOP2A gene dosage had an inverse prognostic impact in terms of shorter disease-free survival (DFS) and overall survival (OS) times in the entire group and in both the HER-2(-) and HER-2(+) subgroups. The unfavorable prognostic impact of TOP2A gene dosage was maintained in the multivariate Cox regression analysis in the entire group and in HER-2(-) patients. CONCLUSIONS: A high gene dosage of TOP2A determined using qPCR occurs frequently both in HER-2(+) and HER-2(-) tumors and has a strong adverse prognostic impact.
BACKGROUND: Previous studies showed the prognostic and predictive impact of human epidermal growth factor receptor 2 (HER-2) gene alterations analyzed separately and jointly with topoisomerase II α (TOP2A) gene alterations; however, the role of TOP2A gene abnormalities alone has not been thoroughly investigated. Additionally, TOP2A aberrations were typically studied in HER-2-positive (HER-2(+)) tumors because these genes are frequently coamplified. Therefore, the knowledge concerning the impact of TOP2A abnormalities in HER-2-negative (HER-2(-)) patients is scarce. This study aimed to investigate the clinical significance of TOP2Aanomalies in breast cancerpatients with HER-2(-) and HER-2(+) tumors. MATERIALS AND METHODS: Snap-frozen tumor samples from 322 consecutive stage I-III breast cancerpatients were analyzed for TOP2A gene dosage using quantitative real-time PCR (qPCR). RESULTS: A high TOP2A gene dosage was found in 94 tumors (29%)-32% and 27% of HER-2(+) and HER-2(-)tumors, respectively. The mean TOP2A gene dosages in the HER-2(+) and HER-2(-) groups were 1.49 ± 1.03 and 1.09 ± 0.35, respectively. High TOP2A gene dosage had an inverse prognostic impact in terms of shorter disease-free survival (DFS) and overall survival (OS) times in the entire group and in both the HER-2(-) and HER-2(+) subgroups. The unfavorable prognostic impact of TOP2A gene dosage was maintained in the multivariate Cox regression analysis in the entire group and in HER-2(-)patients. CONCLUSIONS: A high gene dosage of TOP2A determined using qPCR occurs frequently both in HER-2(+) and HER-2(-)tumors and has a strong adverse prognostic impact.
Authors: Minna Tanner; Jorma Isola; Tom Wiklund; Björn Erikstein; Pirkko Kellokumpu-Lehtinen; Per Malmström; Nils Wilking; Jonas Nilsson; Jonas Bergh Journal: J Clin Oncol Date: 2006-05-08 Impact factor: 44.544
Authors: A Di Leo; D Larsimont; D Gancberg; T Jarvinen; M Beauduin; A Vindevoghel; J Michel; C H Focan; F Ries; P H Gobert; M T Closon-Dejardin; S Dolci; G Rouas; M Paesmans; J P Lobelle; J Isola; M J Piccart Journal: Ann Oncol Date: 2001-08 Impact factor: 32.976
Authors: Ann S Knoop; Helle Knudsen; Eva Balslev; Birgitte B Rasmussen; Jens Overgaard; Kirsten V Nielsen; Andreas Schonau; Katrín Gunnarsdóttir; Karen E Olsen; Henning Mouridsen; Bent Ejlertsen Journal: J Clin Oncol Date: 2005-10-20 Impact factor: 44.544
Authors: A Rody; T Karn; E Ruckhäberle; V Müller; M Gehrmann; C Solbach; A Ahr; R Gätje; U Holtrich; M Kaufmann Journal: Breast Cancer Res Treat Date: 2008-03-14 Impact factor: 4.872
Authors: Jeffrey S Ross; Jonathan A Fletcher; Gerald P Linette; James Stec; Edward Clark; Mark Ayers; W Fraser Symmans; Lajos Pusztai; Kenneth J Bloom Journal: Oncologist Date: 2003
Authors: Aleksandra Markiewicz; Marzena Wełnicka-Jaśkiewicz; Barbara Seroczyńska; Jarosław Skokowski; Hanna Majewska; Jolanta Szade; Anna J Żaczek Journal: Am J Transl Res Date: 2014-11-22 Impact factor: 4.060